Prognostic test for Multiple Myeloma

Murie et al.

1 Individualized dynamic risk assessment for multiple

2 myeloma

- 3
- 4
- 5 Carl Murie¹, Serdar Turkarslan¹, Anoop Patel², David G. Coffey³, Pamela S. Becker⁴, Nitin
- 6 S. Baliga^{1,5,6,7,8,*}
- 7
- 8 ¹Institute for Systems Biology; Seattle, WA, USA
- 9 ²Department of Neurosurgery, Duke University; Durham, NC, USA
- 10 ³Division of Myeloma, University of Miami, Miami; FL, USA
- 11 ⁴Departments of Hematology and Hematopoietic Stem Cell Transplantation and Hematologic
- 12 Malignancies Translational Science, City of Hope National Medical Center; Duarte, CA, USA
- ⁵Molecular Engineering and Sciences Institute, University of Washington; Seattle, WA, USA
- ⁶Departments of Biology and Microbiology, University of Washington; Seattle, WA, USA
- ⁷Molecular and Cellular Biology Program, University of Washington; Seattle, WA, USA
- 16 ⁸Lawrence Berkeley National Lab, Berkeley; CA, USA
- 17
- 18 Running title: Prognostic test for multiple myeloma
- 19 *corresponding author
- 20 Nitin S. Baliga: <u>nitin.baliga@isbscience.org</u>
- 21 401 Terry Ave N
- 22 Seattle, WA 98109
- 23 T: 206.732.1266
- 24 ORCID: 0000-0001-9157-5974
- 25

Prognostic test for Multiple Myeloma

Murie et al.

26 Abstract

Background. Individualized treatment decisions for patients with multiple myeloma (MM)
 requires accurate risk stratification that takes into account patient-specific consequences
 of genetic abnormalities and tumor microenvironment on disease outcome and therapy
 responsiveness.

Methods. Previously, SYstems Genetic Network AnaLysis (SYGNAL) of multi-omics 31 tumor profiles from 881 MM patients generated the mmSYGNAL network, which 32 uncovered different causal and mechanistic drivers of genetic programs associated with 33 disease progression across MM subtypes. Here, we have trained a machine learning (ML) 34 algorithm on activities of mmSYGNAL programs within individual patient tumor samples 35 36 to develop a risk classification scheme for MM that significantly outperformed cytogenetics, International Staging System, and multi-gene biomarker panels in 37 38 predicting risk of PFS across four independent patient cohorts.

Results. We demonstrate that, unlike other tests, mmSYGNAL can accurately predict
 disease progression risk at primary diagnosis, pre- and post-transplant and even after
 multiple relapses, making it useful for individualized dynamic risk assessment throughout
 the disease trajectory.

43 Conclusion. mmSYGNAL provides improved individualized risk stratification that
44 accounts for a patient's distinct set of genetic abnormalities and can monitor risk
45 longitudinally as each patient's disease characteristics change.

Prognostic test for Multiple Myeloma

Murie et al.

47 BACKGROUND

Multiple Myeloma (MM) is characterized by uncontrolled proliferation of malignant plasma 48 49 cells originating in the bone marrow and overproduction of monoclonal immunoglobulin or M-protein. Improvements in treatments based on better knowledge of underlying 50 pathology have improved median overall survival (OS) to >6 years.⁽¹⁾ Prognosis is 51 primarily assessed by revised International Staging System (R-ISS)⁽²⁾ that combines 52 levels of β -2 microglobulin, serum albumin, lactate dehydrogenase activity, and 53 cytogenetics at diagnosis. Fluorescence in situ hybridization (FISH) is used to define high-54 risk MM based on the presence of specific cytogenetic abnormalities, including 55 chromosomal translocations involving the immunoglobulin heavy chain (e.g., t(4:14) and 56 57 t(14;16)), and amplifications of regions involving oncogenes (amp1g) or deletions of tumor suppressors (del(17p)) that portend a shorter progression-free survival (PFS) and OS.⁽³⁻ 58 59 ⁷⁾ While recent advancements like Seq-Fish show promise in improving the identification 60 of chromosomal abnormalities and merit evaluation for their potential contributions to 61 refining risk prediction models, FISH remains the current standard in most clinical laboratories.⁽⁸⁾ However, FISH testing alone is insufficient to risk stratify MM since many 62 patients with the same cytogenetic abnormality experience varied lengths of PFS and OS, 63 64 suggesting potential to further improve outcomes with finer grained risk stratification. Accordingly, many studies have used gene expression profiling to better understand 65 subtypes and stages of MM progression.⁽⁹⁻¹⁴⁾ In particular, two multigene biomarker 66 67 panels, SKY92 (EMC-92) and GEP70 (UAMS-70), that use expression patterns of 92 and 68 70 genes, respectively, were commercialized into clinical tests to predict risk of disease progression.^(15, 16) While gene expression panels are not routinely used in clinical practice 69 70 they continue to play a role in advancing research efforts.⁽¹⁷⁻¹⁹⁾ Recognizing their role in 71 research, it is evident that there exists an unmet need to develop more accurate tools for 72 risk assessment. In particular, a clinical test to longitudinally assess MM prognosis at 73 various stages could prove transformational in improving outcomes by enabling dynamic 74 calibration of personalized treatment plans based on the unique disease trajectory of each patient.(20-24) 75

76

77 Wall et al. advanced SYstems Genetic Network AnaLysis (SYGNAL) with Mining for

Prognostic test for Multiple Myeloma

Murie et al.

78 Node-Edge Relationships (MINER) to analyze multi-omics data from an 881 patient 79 cohort and construct a transcriptional regulatory network for MM (mmSYGNAL).⁽²⁵⁾ 80 mmSYGNAL delineated how subsets of mutations across the patient cohort causally 81 modulated mechanistic regulators of co-regulated genes across ~3,000 regulons. Further, through clustering of regulons, mmSYGNAL identified 141 genetic programs 82 whose activity profiles stratified patients into ~25 transcriptional states that were more 83 predictive of clinical outcome than cytogenetic subtyping. In fact, the genetic programs 84 also uncovered subtype-specific causal and mechanistic drivers of MM progression. 85 Additionally, mmSYGNAL also explained how patients escaped treatment and relapsed, 86 87 by providing insight into mechanisms of resistance manifesting from cellular and molecular interactions within the tumor microenvironment. mmSYGNAL demonstrated, 88 89 for example, that network activity of targets of FDA-approved standard of care (SOC) 90 drugs had decreased significantly at relapse, but also suggested that MM recurrence in 91 some patients was associated with increased sensitivity to other investigational therapies. 92 These findings suggested that mmSYGNAL could potentially serve as a prognostic as 93 well as a predictive tool to stratify risk and to personalize therapy regimen based on the activity profiles of genetic programs containing drug targets. 94

95

Here, we report a MM prognostic risk prediction framework based on mmSYGNAL 96 97 program activity profiles within a patient's myeloma cells. Specifically, we applied elastic net regression to identify programs within the mmSYGNAL network, whose activity 98 99 profiles accurately predicted risk of disease progression in each individual across the 881 patient cohort. By training the ML algorithm on subsets of patients, we developed models 100 101 that provided finer grade risk stratification within cytogenetic subtypes of MM. We have 102 combined these models into an mmSYGNAL risk prediction framework that was tested 103 on four independent MM cohorts (three microarray datasets from cohorts of newly 104 diagnosed patients and one RNASeg dataset from a prospective double-blind study on a 105 cohort of patients sampled at varied stages of the disease). These independent cohort 106 studies demonstrated that risk prediction with mmSYGNAL significantly outperformed 107 cytogenetics, ISS, and multi-gene biomarker panels (SKY92 and GEP70), especially 108 across different disease stages, including primary diagnosis, pre- or post-transplant, and

Prognostic test for Multiple Myeloma

Murie et al.

- 109 even after multiple relapses. Finally, we discuss how the causal and mechanistic
- 110 underpinnings of genetic programs used for risk prediction also provided actionable
- 111 insight into the selection of appropriate therapies for each patient.

Prognostic test for Multiple Myeloma

Murie et al.

113 Materials and Methods

114 Study Design. The mmSYGNAL risk prediction models were generated with a training 115 data set and performance was analyzed with six independent validation data sets. The Interim Analysis 12 (IA12) dataset from the CoMMpass study was acquired from the 116 Multiple Myeloma Research Foundation (MMRF) and consisted of RNASeq and 117 cytogenetic data for 881 patients and matched clinical outcomes for 769 patients.⁽²⁶⁾ The 118 119 mmSYGNAL model was generated with the IA12 dataset in 2021 and while the newer 120 IA18 dataset from the same CoMMpass study did not provide sufficient numbers of new 121 patients to justify training a new model, it did provide an independent set of relapse 122 patients for testing model performance. The RNASeg read counts were TMM normalized. 123 transformed into TPM values, and Z-scored by each sample and across the cohort. Seven 124 cytogenetic abnormality risk subtypes were identified in this cohort with six based on FISH (t(4;14), t(11;14), del(17p), del(1p), del(13), amp(1q)) and one based on overexpression 125 of FGFR3 as a proxy for t(4:14).^(27, 28) 126

127

Three Affymetrix data sets of 559 (GSE24080⁽²⁹⁾), 282 (GSE19784⁽¹³⁾) and 426 128 (GSE136337⁽³⁰⁾) patients with matching clinical outcomes, were normalized as described 129 130 in their respective papers. A fourth dataset obtained through the Seattle Cancer Care 131 Institute (SCCA) consisted of RNASeq, cytogenetics and clinical outcome data for 23 patients at varied disease stages.⁽³¹⁾ The RNASeg data for the SCCA cohort was 132 normalized similarly to the IA12 data set. Age and gender distributions for all data sets 133 134 are shown in **Table 1**. Patients within each cohort were sub-grouped into low-, high-, and 135 extreme-risk classes (Table 2) based on Guan scores (Supplementary Methods).⁽³²⁾

136

137 **Construction of risk prediction models based on genetic program activities within** 138 **the mmSYGNAL network model.** mmSYGNAL is a transcriptional regulatory network 139 model inferred from IA12 data (**Supplementary Methods**). Gene expression and survival 140 data from the IA12 cohort (n=769) were used to build risk prediction models for all patients 141 (subtype-agnostic), and for the seven cytogenetic abnormality risk subtypes (t(4;14), 142 del(1p), del(13), amp(1q), and *FGFR3* (**Table S1**). Programs were discretized as over 143 (+1), neutral (0), or under (-1) active, based on distribution of z-scored values of member

Prognostic test for Multiple Myeloma

Murie et al.

144 genes, as described previously.(25) Clinical outcomes were transformed to Guan score 145 and discretized to low-, high- and extreme-risk groups (Fig. S1).(32) Elastic net 146 regression (with bootstrapping and jackknife cross-validation to avoid overfitting) was 147 applied to identify programs whose activities could stratify patients into risk classes. 148 Training was performed on all or subsets of patients to generate sub-type agnostic or subtype-specific models, respectively, except for del(17p) and t(11;14) subtypes, which 149 150 had insufficient numbers of patients for model training.⁽³³⁾ Analysis of RNASeq profiles 151 from CD138+ myeloma cells with appropriate models was used to classify patients into 152 low- or high-risk if the score was less (or greater) than the standard machine learning 153 cutoff of 0.5, and as 'extreme' if the score was >0.6. A cutoff of 0.6 also stratified 154 approximately ~10% of all patients into extreme risk subgroup, which was consistent with the proportion of patients in this subgroup based on actual clinical outcome. 155

156

Risk prediction using gene expression panels. SKY92 and GEP70 risk scores were
produced with R code from the DREAM challenge⁽³⁴⁾, after ascertaining that our
implementation reproduced Kaplan-Meier (KM) plots in the original papers (Fig. S2).
Patients were classified as high- or low-risk if the score was higher or lower than a cutoff
value reported in the original papers (SKY92=0.827 and GEP70=0.66).^(15, 16)

162

Statistical Analysis. Log-rank tests were used to evaluate the risk stratification of KM
 curves, and AUCs of ROC curves were used to evaluate accuracy of risk prediction. (More
 details on statistical analysis are in Supplementary Information: Methods)

Prognostic test for Multiple Myeloma

Murie et al.

167 **RESULTS**

168 mmSYGNAL scheme for predicting risk of disease progression for an individual 169 MM patient

170 Previous work has shown that activity profiles of 141 programs in the mmSYGNAL 171 network grouped 881 MM patients in the IA12 cohort into 25 transcriptional states, each associated with distinct median length of PFS.⁽²⁵⁾ Interestingly, patients with the same 172 173 chromosomal abnormality were distributed across multiple low- and high-risk states, 174 which indicated that cytogenetics alone was insufficient to accurately estimate risk of disease progression. Remarkably, activities of just two programs sub-stratified patients 175 within each cytogenetic subtype (e.g., t(4:14)) into extreme (median PFS ~5 months), 176 177 high (median PFS ~22 months) or low (median PFS ~30 months) risk subgroups. Building on this observation, we applied elastic net regression and identified 25 programs whose 178 179 activity patterns accurately stratified 769 IA12 patients into low-, high- and extreme-risk 180 groups. This model, which was trained on all patients, will here onwards be referenced as the "subtype-agnostic model". We investigated risk prediction on a cytogenetic subtype 181 182 basis as MM is increasingly being considered as a collection of related diseases 183 characterized by different cytogenetic abnormalities, prognoses and responses to therapy, with distinct transcriptional profiles.⁽³⁵⁻³⁷⁾ Accordingly, for each of five cytogenetic 184 185 subtypes, t(4:14), del(1p), del(13), amp(1q), and FGFR3 (a proxy for t(4:14)), that were 186 statistically well-represented in the patient cohort, a separate subtype-specific risk 187 prediction model was trained (Methods). Performance of each model was evaluated on 188 the IA12 dataset by calculating Area Under the Curve (AUC) of the Receiving Operating 189 Characteristic (ROC) (Fig. 1A). Each risk model was assigned a grade based on their 190 AUC score; t(4;14) and FGFR3 models (AUC > 0.9) received an 'A' grade; amp(1g), 191 del(1p), and del(13) (0.8 >AUC< 0.9) were assigned a 'B' grade, and subtype-agnostic 192 model (AUC<0.8) was assigned a 'C' grade. Unsurprisingly, AUCs for combined ROC 193 curves within A, B, and C grade models also rank ordered in a similar fashion with AUCs 194 of 0.915, 0.848, and 0.724 respectively (Fig. 1B). There was significant separation 195 between the low-, high- and extreme-risk survival curves (log rank test p-value<=1.2e-196 0.9) with distinct median PFS (34-44 months for the low-risk group, 19-28 months for the 197 high-risk group and 6-14 months for the extreme-risk group; Fig. 1C. Table 3). Risk

Prognostic test for Multiple Myeloma

Murie et al.

prediction using all models across the 769 patients within the IA12 dataset yielded an
AUC value of 0.77 (Fig. 1D and E).

200

201 mmSYGNAL significantly outperforms cytogenetics in predicting risk of disease 202 progression in MM

203 Newly diagnosed MM patients with one or more high-risk chromosomal abnormalities, 204 del(17p), t(4:14) and t(14:16), are considered by R-ISS to be at highest risk of disease progression³. However, there was high variability in disease outcome within cytogenetic 205 206 subtypes and ISS stages across all data sets, which demonstrated that these classification methods are suboptimal in risk stratification (Fig. S3). We investigated the 207 208 prognostic value of risk prediction based solely on cytogenetics by performing survival 209 analysis of IA12 cohort patients stratified by the number of high-risk chromosomal 210 abnormalities, viz. del(17p), t(4;14), t(14;16), and FGFR3. While the Kaplan-Meier (KM) 211 plots showed proportional increase in risk of disease progression with the number of 212 chromosomal abnormalities (Fig. 2A, Table 4), the number of cytogenetic abnormalities 213 alone did a poor job of rank ordering patients on risk (AUC: 0.53) relative to the mmSYGNAL risk model (AUC: 0.65, Fig. 2B). While mmSYGNAL improved accuracy of 214 215 predicting risk of disease progression in patients sub-grouped by numbers of high-risk 216 cytogenetic abnormality (AUC=0.58), the overall performance was best with mmSYGNAL 217 alone (AUC: 0.65). Finally, survival analysis also demonstrated that, relative to 218 cytogenetic abnormalities, activities of transcriptional programs are better prognostic 219 markers for MM (Fig. 2C).

220

221 mmSYGNAL outperforms ISS and multigene biomarker panels GEP70 and SKY92

We compared performance of mmSYGNAL risk prediction to GEP70 and SKY92, which use expression levels of 70 and 92 genes, respectively, to estimate risk of disease progression.^(15, 16) The ISS prognostic classifier (the current standard R-ISS classification was not available) was also included as it is the standard of risk assessment for newly diagnosed patients.⁽²⁾ Accuracy of risk classification by the four approaches was tested on three cohorts (IA12, GSE19784, GSE24080). While mmSYGNAL was trained on the

Prognostic test for Multiple Myeloma

Murie et al.

IA12 cohort (albeit with jackknife cross-validation to avoid overfitting), GSE19784 and
GSE24080 were independent and as such served as ideal test datasets. Importantly,
SKY92 was developed with GSE24080, and expected to perform best on this dataset.
Moreover, both RNASeq (IA12) and microarray (GSE19784 and GSE24080) data are
included allowing for assessment of model performance on disparate technology
platforms.

234 The performance of mmSYGNAL, GEP70, and SKY92 were similar on the IA12 data set 235 (AUCs of 0.65, 0.65, and 0.60, respectively) and GSE24080 (AUCs of 0.69, 0.70 and 236 0.70, respectively). Interestingly, ISS performed the worst across all data sets with AUC 237 scores of 0.61, 0.46 and 0.64 for IA12, GSE19784 and GSE24080, respectively. While mmSYGNAL performance on GSE19784 with an AUC of 0.65 was slightly lower than 238 239 GEP70 (AUC: 0.69) and SKY92 (AUC: 0.73), further analysis revealed that this might be 240 because the two panels had identified few high-risk patients in both cohorts (Fig. 3A). KM 241 survival analysis demonstrated that mmSYGNAL, SKY92 and GEP70 were all effective 242 in classifying patients into high- and low-risk groups (Fig. 3B), with median PFS values 243 that were distinct for each dataset, but similar across all three approaches (Table 5). Again, ISS performance was the worst, particularly so for the GSE19784 data set with 244 245 little separation between risk groups, and lower median PFS for Stage relative to Stages 246 II and III. Importantly, only mmSYGNAL identified extreme-risk patients.

Finally, notwithstanding the significant overlap across methods, each method had identified distinct sets of high-risk patients (**Fig. 3C**). Interestingly, for the GSE19784 cohort, while SKY92 and GEP70 correctly identified only 11 and 22 high-risk patients, respectively, mmSYGNAL correctly identified 40 high-risk patients. Thus, the higher true positive rate of the two gene panels in identifying high-risk patients (95% for SKY92 and 100% for GEP70) relative to mmSYGNAL (82%) (**Fig. 3D**) came at the cost of significantly lower sensitivity, particularly so for SKY92.

254

255 mmSYGNAL subtype-specific risk models outperform the subtype-agnostic model
 256 Consistent with the hypothesis that MM is a collection of diseases characterized by
 257 different chromosomal abnormalities with distinct transcriptional profiles, overlapping but

Prognostic test for Multiple Myeloma

Murie et al.

258 distinct subsets of programs contributed to risk of disease progression for each subtype 259 of MM (Fig. S4). While subtype-specific risk models significantly outperformed the 260 subtype-agnostic model in the IA12 dataset (Fig. 1A), only the t(4;14) model could be 261 evaluated on 13 and 27 t(4;14) patients in GSE19784 and GSE24080, respectively (Table 262 **S1**). Therefore, performance of del(13) del(1p) and amp(1q) subtype-specific models were tested on a fourth dataset (GSE136337) with 77, 90, and 4 patients, respectively. 263 264 While GEP70 or SKY92 risk scores could not be calculated due to unavailability of 265 matching probe sets, the clinical metadata includes GEP70 risk classifications (high or 266 low) and ISS stage for each patient. While all methods were effective at risk stratifying all 267 patients (minimum p-value: 2.2e-04), the mmSYGNAL agnostic model outperformed 268 GEP70 and ISS (Fig. 4A-E). Although median PFS for high- and low-risk groups (25 and 51 months respectively) were similar for the agnostic model and GEP70, only the former 269 270 identified an extreme-risk (median PFS: 16 months) (Fig. 4F). ISS performed worst with 271 median PFS values ranging from 30 to 58 months (Stage I to Stage III). Performance of 272 del(13) and del(1p) subtype-specific models was even better, especially in identifying 273 high-risk (median PFS of 21 months) and extreme-risk groups (median PFS of 9.5 and 4 274 months, respectively). The subtype-specific models were also better at rank ordering 275 patients by risk, generating AUC scores of 0.62, 0.68 and 0.70 for the agnostic, del(1p) 276 and del(13) subtypes, respectively (amp(1q) AUC was 1.0 albeit with only 4 samples). In 277 sum, while cytogenetic abnormality alone was not a robust prognostic marker, subtype-278 specific mmSYGNAL models performed significantly better at predicting risk of disease 279 progression, even relative to the subtype-agnostic risk model.

280

281 mmSYGNAL accurately predicts risk of PFS at varied disease stages, including 282 after multiple relapses

We investigated the effectiveness of the gene panels, mmSYGNAL and ISS for longitudinal monitoring of disease progression risk beyond primary diagnosis. We applied the three risk prediction methods and ISS to 86 relapse patients in the IA18 CoMMpass dataset, who were on their second or third line of treatment. mmSYGNAL outperformed all methods in stratifying patients into low and high/extreme risk groups (KM survival curve p-values: 0.0009 (mmSYGNAL), 0.012 (GEP70), 0.076 (SKY92) and 0.020 (ISS) (**Fig.**

Prognostic test for Multiple Myeloma

Murie et al.

289 5A). The median length of PFS for patients classified as extreme-risk by mmSYGNAL 290 (2.1 months) was comparable to median PFS of patients classified as high-risk by SKY92 291 and GEP70 (2.2 months for both). ISS stage III patients by contrast had significantly 292 longer median PFS of 4.9 months; and there was minimal separation between survival 293 curves for ISS Stage I (20 patients, median PFS: 8.4 months) and II (32 patient; median 294 PFS: 8.1 months). mmSYGNAL also identified a group of high-risk patients with a median 295 PFS of 6.1 months (Fig. 5B). Relative to high/extreme-risk patients, there was greater 296 separation in mmSYGNAL survival curves for low-risk patients with median PFS of 8.1 297 months, as compared to median PFS of 7.4 months for SKY92 and GEP70. Importantly, 298 mmSYGNAL identified a greater number of patients as extreme or high-risk (41 patients) 299 than both GEP70 (18 patients), SKY92 (21 patients, Fig. 5C).

300

301 After establishing superior performance of mmSYGNAL in risk assessment of relapsed 302 patients, we performed a double-blind study to evaluate performance of all methods across disease stages (primary diagnosis, pre- and post-transplants, and after multiple 303 304 relapses). In this double-blind study, RNASeq was performed on CD138+ bone marrow 305 mononuclear cells from 23 patients, including 8 newly diagnosed, 8 relapsed refractory 306 (median of 5 relapses), and 7 pre- or post-transplant patients (SCCA). Notably, the cohort 307 also represented diversity in clinical outcomes (OS: 9 -148 months and PFS: 0.7 to 52 308 months; Fig. 5D). Of all approaches tested, only mmSYGNAL was accurate in risk 309 stratification (Fig. 5E). Regardless of their disease stage, mmSYGNAL stratified the 23 310 patients into distinct risk groups (p-value=0.001): 12 in the low-risk group, 7 in the high-311 risk group and 4 in the extreme-risk group. Although there was separation in survival 312 curves of patients stratified by cytogenetics, the risk stratification was not significant (p-313 value=0.101), with longer median PFS for the extreme-risk group relative to the high-risk 314 group (24 vs 3 months, respectively). By contrast, mmSYGNAL differentiated among all 315 three risk groups with median PFS of 52 months for high-risk and 1 month for extreme-316 risk patients; the survival curve for the low-risk patients did not cross the 50% probability 317 threshold (Fig. 5E). These results underscore the limitations of cytogenetics-based risk 318 stratification, especially for patients with high-risk cytogenetic subtypes of MM, further 319 motivating the need for a mmSYGNAL-type risk stratification approach.

Prognostic test for Multiple Myeloma

Murie et al.

320

321 Risk prediction by both gene expression panels performed poorly across all patients, with 322 GEP70 calling all but one patient (P-21) high-risk, and SKY92 stratifying all patients into the high-risk group (Fig. S5). Interestingly, while mmSYGNAL risk scores were inversely 323 324 correlated with length of PFS across all patients (r = -0.38), no correlation with PFS was observed for risk scores generated by SKY92 (r=0.1) and GEP70 (r=0.01, Fig. S5). 325 326 Except for patient P-21, all patients with multiple relapses (P-1, P-2, P-4, P-10, P-14, P-327 20, P-25) were classified as high-risk by cytogenetic subtyping (Table S2). Yet, 328 mmSYGNAL sub-stratified these patients into extreme-risk (P-2, P-10 and P-20), high-329 risk (P-1 and P-4), and low-risk (P-14, P-21 and P-25). Apart from P-25, who was 330 misdiagnosed as low-risk, mmSYGNAL risk categorization was accurate across all three 331 risk groups (Fig. 5F). In fact, mmSYGNAL risk scores were significantly anticorrelated 332 with length of PFS for all relapsed patients (r=-0.81), even upon excluding P-21 (r=-0.64), whose significantly longer PFS was an outlier. In contrast, the association between 333 GEP70 and SKY92 risk scores and PFS were weaker, especially after removing P-21 334 335 (GEP70: r = -0.01; SKY92: r = -0.29). Thus, this study demonstrated the effectiveness of 336 mmSYGNAL for longitudinally monitoring the risk of disease progression in a patient, 337 regardless of the stage of the disease -at primary diagnosis, pre- and post-transplant, 338 and even after multiple relapses.

339

Risk-associated programs are significantly associated with targeted cancer therapies

342 We hypothesized that the dynamic risk assessment capability of mmSYGNAL was likely 343 because the model was built upon causal and mechanistic principles, which could also 344 potentially aid in drug discovery and therapy selection. To test this hypothesis, we 345 performed survival analysis and discovered that only 25 of the total 141 programs had 346 contributed significantly in varied weighted combinations to risk prediction by at least one 347 model (Fig. 6A). While 14 programs were essential for risk prediction by a single model 348 (e.g., Pr-98 for amp1(g) model, and Pr-110 for the subtype-agnostic model), 11 programs 349 were important across multiple models (e.g., Pr-61 (4 models), Pr-104 (5 models) and Pr-350 0 (5 models)). Strikingly, under-activity of 20 programs predicted poor PFS, whereas over-

Prognostic test for Multiple Myeloma

Murie et al.

351 activity of just 5 programs were associated with poor prognosis. The under- and over-352 activity of risk stratifying programs was consistent with dysregulation of similar gene sets 353 in other cancers with poor prognosis. For example, Pr-0, a significant prognostic marker 354 of disease progression across all subtype-specific models, was enriched for genes that 355 have been associated with at least four other cancers (angioimmunoblastic lymphoma, leukemia, neuroblastoma, and bladder cancer).⁽³⁸⁻⁴¹⁾ Another evidence for mechanistic 356 357 association of risk stratifying programs with etiology of MM was the overrepresentation of 358 genes that are differentially regulated during early and late stages of normal differentiation 359 from tonsil B cells -> tonsil plasma cells -> bone marrow plasma cells, with distinct expression patterns in MM plasma cells⁽⁹⁾ (Table S3, File S2). 360

361

If the programs were causally and mechanistically associated with disease progression, 362 363 then we predicted that they should contain a significant number of targets of anticancer 364 drugs, including MM therapies. Indeed, the 25 risk-associated programs were significantly 365 enriched (Fischer exact test p-value=0.0003) for targets of 129 out of 399 drugs used for 366 MM, in a Phase IV cancer trial, or in at least a Phase I MM trial. Strikingly, consistent with 367 their mechanism of action, targets of 28 agonists and 88 antagonists were in programs 368 associated with bad prognosis when they were under- and over-active, respectively 369 (Fisher exact test p-value=0.0006; **Supplementary Methods)**. This list included targets of drugs used in SOC for MM, such as dexamethasone^(42, 43) and prednisone^{32,33} both of 370 371 which are agonists that target the human glucocorticoid receptor NR3C1, a TF of regulon 372 R-3191 in Pr-104. Specifically, mmSYGNAL implicated NR3C1 in transcriptional 373 activation of regulons within Pr-104 (Cox HR=0.66, 95% CI=(0.57, 0.77), p-value=1.510⁻ 374 ⁷) and Pr-110 (Cox HR=0.67, 95% CI=(0.56, 0.80), p-value=9.610⁻⁶), and Pr-69, which 375 was not included in the risk models but had significant risk association (Cox HR=1.52, 376 95% CI=(0.1.29, 0.1.81), p-value=7.410⁻⁷). In all three cases (Pr-104, Pr-110, Pr-69) an 377 agonist acting on NR3C1 would differentially regulate each program in a therapeutic 378 direction, i.e., towards a low-risk state (up-regulating Pr-104 and Pr-110 and down-379 regulating Pr-69) (Fig 6B and Fig. S6). Thus, these findings demonstrate the potential for 380 leveraging the causal and mechanistic association of risk-associated programs to further 381 develop mmSYGNAL into a predictive test for discovery of novel targets, repurposing

Prognostic test for Multiple Myeloma

Murie et al.

- 382 drugs approved for other indications, and selecting therapeutic interventions based on
- the activity profiles of disease-driving programs in each patient.

Prognostic test for Multiple Myeloma

Murie et al.

385 **DISCUSSION**

386 Personalized clinical care decisions including treatment selection for newly diagnosed 387 MM patients is based on prognostic biomarkers such as chromosomal abnormalities that 388 are still hindered by significant variability in survival outcomes. Given the poor accuracy 389 of cytogenetics and the lack of use of gene expression panels there is an unmet need for 390 improved risk assessment tools in the clinical setting. For example, in the IA12 cohort, 391 53% of patients with t(4;14) or FGFR3 (high-risk chromosomal abnormalities) actually had 392 good prognosis (long PFS). Alternatively, presumed low-risk patients with t(11:14) or no 393 chromosomal abnormalities had significant proportions (37% and 32%, respectively) with shorter PFS.⁽²⁵⁾ In this regard, risk stratification based on mmSYGNAL program activities 394 395 significantly improved risk stratification, even within cytogenetic subtypes, demonstrating 396 that transcriptional states of myeloma cells are more accurate than cytogenetic 397 abnormalities at predicting disease progression. Furthermore, our risk prediction models 398 were tested using the IA12 data, incorporating updated cytogenetic annotations derived 399 from Seq-FISH classifications. The results showed comparable or improved performance, 400 underscoring the robustness and accuracy of our models (Supplementary Information 401 **S7**). Interestingly, GEP70 and SKY92 also performed comparably across IA12, 402 GSE19784 and GSE24080, further demonstrating that gene expression patterns do 403 indeed contain valuable information regarding disease etiology. However, only 404 mmSYGNAL was accurate in predicting dynamic risk across the disease trajectory of a 405 patient.

406

407 The relatively poorer risk prediction by cytogenetics and gene expression panels, 408 especially in later stages of MM, is likely because they are based on correlates of clinical 409 outcomes and not directly associated with causal and mechanistic drivers of disease 410 progression. The myriad mutations in myeloma cells of MM patients act in complex 411 combinations that are both contextual in the bone marrow microenvironment and too large 412 in number to model in a statistically significant manner. However, the consequences of 413 the mutations were captured by mmSYGNAL in the architecture and activity patterns of 414 regulons and programs that were associated with disease progression in a biologically and clinically meaningful manner.⁽²⁵⁾ Additionally, the improvement of cytogenetics-based 415

Prognostic test for Multiple Myeloma

Murie et al.

416 risk stratification upon including program activity suggests that other mutations as well as 417 non-genetic factors, such as the microenvironment, have major influence on disease 418 prognosis.⁽⁴⁴⁻⁴⁸⁾ While it is complicated to measure specific microenvironment characteristics, the activity patterns of regulons and programs within mmSYGNAL already 419 420 seems to account for many of these non-genetic influences as previously demonstrated by its ability to recapitulate mechanisms of microenvironment-induced drug resistance 421 422 and immune suppression within the bone marrow of relapse patients.⁽²⁵⁾ There is great 423 potential to further improve the predictive power of mmSYGNAL by incorporating other risk factors considered in the R-ISS, including proportion of plasma cells and other cell 424 425 types in the bone marrow aspirate and M-protein abundance -information that was 426 unfortunately not available for any of the multiple patient cohorts analyzed in this study.

427

428 In addition to a prognostic tool for dynamic risk assessment of MM patients, there is also 429 a need for a predictive tool that can inform clinicians on selecting non-SOC drugs matched 430 to the characteristics of a patient's disease. In particular, while there is broad consensus 431 on SOC therapy for MM, there is greater uncertainty for choosing drugs for relapsed refractory MM patients.^(4, 49-51) In this regard, mmSYGNAL could be developed further into 432 433 a predictive tool for discovering and tailoring existing and new therapies to the unique 434 biological characteristics of a patient's disease. Our discovery that FDA-approved anti-435 cancer therapies (in particular SOC and investigational MM drugs) were enriched within 436 risk-associated programs lends credibility to this strategy. Specifically, our findings 437 suggest that activity patterns of disease-associated programs in myeloma cells could be 438 leveraged in a rational approach to select appropriate therapies, including novel drugs. 439 For instance, Pr-0 and Pr-86, associated with bad prognosis when under-active, were 440 enriched in genes that were upregulated in myeloma cells exposed to Aplidin (plitidepsin, 441 enrichment p-values: 5.37E-10 and 2.23E-2, respectively). Aplidin, a marine-derived anti-442 myeloma compound, inhibits proliferation of myeloma cells by inducing apoptosis⁽⁵²⁾ and 443 is in Phase 3 clinical trial (NCT01102426) in combination with dexamethasone for relapsed refractory MM.⁽⁵³⁾ We hypothesize that high-risk patients with under-active Pr-0 444 and Pr-86 would likely benefit from Aplidin treatment (see File S2 for additional examples 445 446 for selecting drugs based on program activity profiles). Thus, by virtue of its causal and

Prognostic test for Multiple Myeloma

Murie et al.

- 447 mechanistic association with the etiology and progression of MM, mmSYGNAL has the
- 448 demonstrated utility as a prognostic tool for individualized dynamic risk assessment along
- 449 the disease trajectory, and the potential for development into a predictive tool for selecting
- 450 treatments that specifically target disease drivers in each patient.

Prognostic test for Multiple Myeloma

Murie et al.

451 Additional Information

452 Author contributions: N.S.B., P.S.B. and D.G.C conceived the project and designed 453 experiments. P.S.B and D.G.C. provided and curated the patient-derived biopsy tumor 454 specimens and RNA-seq data. C.M., S.T., A.P., P.S.B., D.G.C., and N.S.B. performed 455 and/or contributed to data analysis and interpretation. C.M., S.T., A.P., P.S.B., D.G.C., 456 and N.S.B. drafted and edited the manuscript.

457 Data availability:

458 Data. Microarray data are available at: GSE19784, GSE24080 and GSE136337. IA12

459 and IA18 data can be requested from MMRF. SCCA data can be requested from

- 460 <u>pbecker@coh.org.</u>
- 461 <u>Code</u>.

462 mmSYGNAL risk prediction models: https://github.com/baliga-lab/mmSYGNAL-risk-463 prediction-models

464 mmSYGNAL (original code base): https://github.com/baliga-lab/miner

465 MINER (updated interface): <u>https://github.com/baliga-lab/miner3</u>

466

467 **Competing interests**:

NB is a co-founder and member of the Board of Directors of Sygnomics, Inc., which will commercialize the SYGNAL technology. AP and ST have equity stakes in Sygnomics, Inc. The terms of these arrangements have been reviewed and approved by ISB and Duke University in accordance with their conflict-of-interest policies. PB received institutional research support from Glycomimetics, Pfizer, Notable labs, and is an advisor to Accordant Health Services (CVS Caremark).

474

Funding Information: This work was supported by a NCI-5R01Al141953-04 (N.S.B.),
NSF1565166 (N.S.B.), NCI-5R01CA259469-02, NSF2042948. And Washington
Research Foundation Funding (N.S.B.), a grant from the Brotman Baty Institute for
Precision Medicine (UW) Catalytic Collaboration Grant (DGC and PSB), and a private

Prognostic test for Multiple Myeloma

Murie et al.

- 479 donation to the University of Washington Foundation. This research was funded in part
- 480 through the NIH/NCI Cancer Center Support Grant P30 CA015704 (PI Thomas Lynch,
- 481 MD). The Multiple Myeloma Research Foundation generously made available the Interim
- 482 Analysis 12 (IA12) version of the CoMMpass clinical trial data.

Prognostic test for Multiple Myeloma

Murie et al.

484 Tables

485

486 **Table 1: Age and gender distributions of patients in the training and validation data sets.**

487 Model was trained on the IA12 data and validated with the GSE19768, GSE24080, SCCA,

488 GSE136337 and IA18 relapse data sets. Note that 6 patients in the IA18 relapse data set have

both second- and third-line treatments and are thus repeated in the analysis which resulted in a

- total of 86 samples.
- 491

	IA12		GSE19784 GSE24		080 SCCA		GSE136337		IA18			
	(n=769)		(n=282)		(n=559)		(n=23)		(n=426)		relapse	
											n=(8	0)
Age	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male
25-35	0	3	1	3	0	1	0	0	2	0	0	0
35-45	9	14	14	17	3	3	1	0	15	21	2	1
45-55	40	55	31	52	24	31	3	3	42	57	3	3
55-65	78	117	72	86	62	89	6	2	64	106	6	14
65-75	87	129	3	3	81	129	2	2	41	77	15	17
75-85	37	49	0	0	50	80	1	3	1	0	9	10
85-95	6	9	0	0	2	4	0	0	0	0	0	0

Prognostic test for Multiple Myeloma

Murie et al.

493 Table 2: Clinical risk group PFS and relapse cutoffs generated from analysis of Guan 494 scores. Guan scores transform survival data, PFS and relapse events, into a single numerical 495 risk score ranging from 0 (low risk) to 1 (high risk). The inflection point for the rank ordered Guan 496 scores for each of the three training (GSE19784, GSE24080, GSE136337) and test (IA12) data 497 sets was identified numerically (Guan=0.5) and used as the separation point between high- and 498 low-risk subjects. The 8 month cutoff for extreme-risk patients was based on half the median 499 progress free survival of high-risk subjects found in Shah et al(54). The PFS values mapped from 500 the Guan score inflection point risk cutoff were virtually identical across all data sets.

Risk	Relapse	PFS (months)
extreme	yes	<= 8 months
high	yes	< 33.5 months and > 8 months
low	any	Not in extreme- or high-risk group

Prognostic test for Multiple Myeloma

Murie et al.

502 Table 3: Median PFS (months) and predicted risk classification sample sizes for the three

503 mmSYGNAL grades.

	Media	n PFS (mo	onths)	n				
Grade	extreme	high	low	extreme	high	low		
А	20.0	20.8	45.2	37	10	59		
В	14.2	23.6	45.2	37	31	257		
С	11.3	23.9	41.3	37	90	642		

Prognostic test for Multiple Myeloma

Murie et al.

505 **Table 4: Median PFS (months) for the high-risk cytogenetic subtype count groups.**

Number of abnormalities	median PFS (months)	n
4	12.7	5
3	23.8	33
2	30.1	81
1	32.6	194
0	39.1	456

Prognostic test for Multiple Myeloma

Murie et al.

507 Table 5: Median PFS (months) for mmSYGNAL, GEP70, and SKY92 across the IA12,

508 **GSE19784 and GSE24080 data**.

Datasets:	IA12			GSE19784			GSE24080		
methods	extreme	high	low	extreme	high	low	extreme	high	low
mmSYGNAL	18.4	27.4	39.9	8.9	20.7	31.5	12.1	28.7	74.1
GEP70	NA	20.0	40.5	NA	6.3	30.6	NA	20.8	74.1
SKY92	NA	15.8	39.1	NA	3.4	28.9	NA	22.3	74.6
ISS category	III	II	Ι	III	II	Ι	III	II	Ι
ISS	26.4	29.7	48.7	26.2	37.3	23.4	37.4	65.9	77.6

Prognostic test for Multiple Myeloma

Murie et al.

510 Figures



511



513 ROC curves and sample sizes (n) of subtype specific mmSYGNAL risk models applied to 769

Prognostic test for Multiple Myeloma

Murie et al.

514 IA12 MM patients. Subtype risk models are organized into 3 grades based on their respective 515 AUC scores (A >= 0.9, 0.9 < B >= 0.8, C < 0 .8). (B) ROC curves for the IA12 patients grouped 516 by the grade of the subtypes exhibited by each patient. A patient may be included in multiple 517 graded groups if they exhibit multiple subtypes. If a patient exhibits 2 or more subtypes in a single 518 grade, then the mean of the risk scores is used. (C) Survival plots associated with each grade 519 with Kaplan-Meier log-rank test p-values. (D) Scheme for precision risk prediction for new patients 520 using the "best" model(s). Per this scheme, the risk score of a patient that exhibits multiple 521 subtypes is calculated using the highest-grade risk prediction model (A > B > C). For example, if 522 a patient exhibited both the t(4;14) and the amp(1q) subtypes then the patient's risk score would 523 be based on t(4:14) subtype model, which had an A grade, rather than the amp(1g) subtype 524 model, which was determined to be of B grade. If a patient exhibits multiple subtypes that are 525 associated with equivalent graded models, then the risk score is calculated as the mean of scores 526 generated by the highest-grade models. The patient's risk classification defaults to the C grade 527 subtype-agnostic model if their MM subtype is not represented by any of the subtype-specific 528 models. (E) ROC curve of the mmSYGNAL best quality risk prediction scheme as described in 529 (D) for the 769 IA12 patients. Extreme risk patients are considered as high risk in the ROC 530 analysis.

Prognostic test for Multiple Myeloma

Murie et al.





Fig. 2: Performance of best guality mmSYGNAL model and cytogenetics. (A) Survival curve 533 534 of risk stratification based on number of high-risk cytogenetic subtypes (t(4;14), t(4;16), del(17p),535 FGFR3, amp(1q)) exhibited by each patient (0 to 4). (B) ROC curve risk ordering based on 536 mmSYGNAL best model, cytogenetics, and patients ordered by mmSYGNAL risk probability 537 within each cytogenetic count group ("both"). (C) Survival curves and KM log-rank p-values for 538 mmSYGNAL best model and cytogenetics risk classification (patients showing zero, one, or more 539 than one high-risk cytogenetic abnormality are considered as low-, high- and extreme-risk groups 540 respectively).

Prognostic test for Multiple Myeloma

Murie et al.



Prognostic test for Multiple Myeloma

Murie et al.

542 Fig. 3: Risk prediction results for mmSYGNAL, GEP70, SKY92 and ISS. Methods were 543 applied to the IA12 training data and two microarray validation data sets (GSE19784 and 544 GSE24080) (A) ROC curves and their respective AUC scores for mmSYGNAL, GEP70 and 545 SKY92. (B) Survival curves and KM log-rank p-values for mmSYGNAL, GEP70, SKY92 and ISS. 546 All survival curves showed very low p-values. minimum p-value: 3.5e-8 except for ISS with 547 GSE19784. (C) Overlap of patients that have been classified as high-risk (high- or extreme-risk 548 for mmSYGNAL) (D) Percentage of correct calls made within the respective methods high- and 549 low-risk classification groups. For example, 58% of the patients classified as high-risk by GEP70 550 applied to the IA12 data were also high-risk patients according to clinical outcome. (E) Table of 551 false positive rates for high (high and extreme) and low risk classification groups.

Prognostic test for Multiple Myeloma

Murie et al.



553

554 Fig. 4: Performance of mmSYGNAL agnostic and subtype-specific models, GEP70 and ISS 555 in the GSE136337 cohort. While we were not able to generate GEP70 or SKY92 risk scores 556 from the processed expression data in the public repository due to unavailability of matching 557 probe sets, the clinical metadata did include the GEP70 risk classifications (high or low) and the 558 ISS stages for each patient and are thus shown in the analysis. Survival curves and KM log-rank 559 p-values for (A) agnostic, (B) del(13) (C) ISS and (D) del(1p) and I GEP70 risk models. (F) Table 560 of median PFS scores for all methods which correspond to the colored vertical dashed lines in 561 the survival curves (red = extreme- risk or ISS stage III, green = high-risk or ISS stage II and blue= 562 low-risk or ISS stage I).

Prognostic test for Multiple Myeloma

Murie et al.





Fig. 5: Descriptive and performance plots for mmSYGNAL, GEP70 and SKY92 applied to
relapse patients. Methods were applied to 23 SCCA patients and 86 IA18 CoMMpass patients.
(A) Survival curves for mmSYGNAL, GEP70, SKY92 and ISS applied to relapse patients from
the IA18 CoMMpass trial (n=86). Tables showing the (B) median PFS values for each method

Prognostic test for Multiple Myeloma

Murie et al.

569 and (C) sample sizes of predicted risk classifications for each method (one patient was missing 570 ISS classification). (D) Swimmer plots for the SCCA patients. The arrows indicate that a patient 571 is still going through treatment while those without arrows are either deceased or are not being 572 followed clinically. The solid circles indicate when the RNASeq samples were obtained, and the 573 solid lines show how long a patient was on a particular treatment before a relapse or refractory 574 event (including death). Note that there is a mixture of samples taken at initial diagnosis and 575 samples taken at different times along the disease trajectory. (E) Survival curves and KM log-576 rank p-values for mmSYGNAL and cytogenetics risk classification. Cytogenetic classification 577 where low-, high- and extreme-risk categories are based on whether a patient exhibits either 0, 578 1, or more than one high-risk subtype, respectively. (F) Scatter plots and associated Pearson's 579 correlations of mmSYGNAL, GEP70 and SKY92 risk scores vs PFS (months) for the 8 multiple 580 relapse/refractory patients. Patient 21's PFS value is an outlier and thus correlations with and 581 without that patient's PFS identify how strongly the outlier influences correlation.

Prognostic test for Multiple Myeloma

Murie et al.



583

584 Fig. 6: Risk-associated programs provide mechanistic insights into the biology of 585 disease progression and therapy selection. (A) Relative importance of programs in risk 586 prediction by subtype-agnostic and each subtype-specific model. Twenty-five programs that 587 were associated with distinct survival outcomes (based on KM analysis, log-rank test p-value 588 <0.05) contributed significantly to risk prediction by at least one model. A number of the 25 programs were significant for multiple programs which resulted in a total of 41 instances of a 589 590 risk-associated program showing significance for a particular subtype. Size of each bubble is 591 proportional to relative importance of a given program in estimating risk as determined by the 592 scaled (0-100) absolute value of the t-statistic for each program generated by the elastic net 593 linear regression model. Color shading of bubbles indicates the difference in median PFS of patients when the program is over-active vs. when it is under-active. For instance, Pr-29 594 595 contributed the most to the del(1p) risk model (size of bubble); median PFS of patients when 596 this program was under-active was 50 months shorter relative to when it was over-active (dark 597 red bubble). (B) The causal mechanistic flow of the regulatory network for Pr-104. The network 598 diagram depicts SYGNAL inferred causal influences of 35 mutations on modulating 14 TFs that 599 were implicated in mechanistic regulation of 102 genes within 14 regulons of Pr-104. 600 Furthermore, 17 drugs in clinical trials for MM (any phase) or any other cancer (Phase IV) are 601 shown with their respective causal flows highlighted (mutations, regulators or genes). Two 602 causal networks show drug targets, NR3C1 (purple) and TP53 (orange), that are regulators of 603 program Pr-104 regulons and a third where the drug target, SRD53 (yellow) is a member of two Pr-104 regulons. 604

Prognostic test for Multiple Myeloma

Murie et al.

605 Supplementary Materials:

- 606 Material and methods
- 607 Table S1
- 608 Table S2
- 609 Table S3
- 610 Fig. S1
- 611 Fig. S2
- 612 Fig. S3
- 613 Fig. S4
- 614 Fig. S5
- 615 Fig.S6
- 616 Fig S7
- 617 Data File S2
- 618
- 619 **Definitions:**
- 620 mmSYGNAL: multiple myeloma SYstems Genetic Network AnaLysis
- 621 MM: Multiple Myeloma
- 622 OS: Overall Survival
- 623 PFS: Progress Free Survival
- 624 FISH: Flourescent In Situ Hybridization
- 625 MINER: MIning for Node-Edge Relationships
- 626 AUC: Area Under the Curve
- 627 ROC: Reciever Operating Curve
- 628 R-ISS: Revised International Staging System
- 629 ISS: International Staging System
- 630 KM: Kaplan-Meier
- 631 IA12: Interim Analysis 12
- 632 IA18: Interim Analysis 18
- 633 GEP: Gene Expression Profile
- 634 CoMMpass: Relating <u>Clinical Outcomes</u> in <u>MM</u> to <u>Personal Assessment</u> of Genetic
- 635 Profile

Prognostic test for Multiple Myeloma

Murie et al.

- 636 SCCA: Seattle Cancer Care Alliance
- 637 FDA: US Food and Drug Association
- 638 MMRF: Mulitple Myeloma Research Foundation
- 639 TMM: Trimmed Mean of M values
- 640 TPM: Transcript Per Million
- 641 DREAM: Dialogue for Reverse Engineering Assessment and Methods

Prognostic test for Multiple Myeloma

Murie et al.

643 **References**

Rajkumar SV. Myeloma Today: Disease Definitions and Treatment Advances. American
journal of hematology. 2016;91(1):90-100.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The
Lancet Oncology. 2014;15(12):e538-48.

Balumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al.
Revised International Staging System for Multiple Myeloma: A Report From International
Myeloma Working Group. Journal of Clinical Oncology. 2015;33(26):2863-9.

Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple
myeloma. Nature Reviews Disease Primers. 2017;3:17046.

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of
multiple myeloma and its clinical implications. Nature Reviews Clinical Oncology. 2017;14(2):10013.

657 6. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al.
658 Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International
659 Myeloma Working Group. Blood. 2016;127(24):2955-62.

660 7. Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int661 J Hematol. 2022;115(6):762-77.

8. Miller C YJ, Derome M, Donnely A, Marrian J, McBride K, Auclair D, Keats J. A
Comparison of Clinical FISH and Sequencing Based FISH Estimates in Multiple Myeloma: An
Mmrf Commpass Analysis. Blood. 2016;128(22):374.

665 9. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular
666 classification of multiple myeloma. Blood. 2006;108(6):2020-8.

Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D, et al. Integrative genomic
analysis reveals distinct transcriptional and genetic features associated with chromosome 13
deletion in multiple myeloma. Haematologica. 2007;92(1):56-65.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, et al.
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle
and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in
Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome. Journal of Clinical
Oncology. 2008;26(29):4798-805.

Prognostic test for Multiple Myeloma

Murie et al.

675 12. Chng WJ, Kumar S, VanWier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular
676 Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research.
677 2007;67(7):2982-9.

Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, et al. Gene expression
profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood.
2010;116(14):2543-53.

Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, et al. Pharmacogenomics
of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4,
as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011;118(13):351224.

Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, et al. A gene
expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406-13.

687 16. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated
688 gene expression model of high-risk multiple myeloma is defined by deregulated expression of
689 genes mapping to chromosome 1. Blood. 2007;109(6):2276-84.

Kuiper R, Zweegman S, van Duin M, van Vliet MH, van Beers EH, Dumee B, et al.
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple
myeloma: the HOVON-87/NMSG-18 trial. Blood Adv. 2020;4(24):6298-309.

693 18. Chen YT, Valent ET, van Beers EH, Kuiper R, Oliva S, Haferlach T, et al. Prognostic gene
694 expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients
695 treated outside clinical trials. Int J Lab Hematol. 2022;44(1):127-34.

- Mohan M, Weinhold N, Schinke C, Thanedrarajan S, Rasche L, Sawyer JR, et al.
 Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of
 chromosome 1q21 gain/amplification and GEP70 status on outcome. Br J Haematol.
 2020;189(1):67-71.
- van Es N. Dynamic prediction modeling for cancer-associated venous thromboembolism.
 Journal of Thrombosis and Haemostasis. 2020;18(6):1276-7.
- Alexander M, Ball D, Solomon B, MacManus M, Manser R, Riedel B, et al. Dynamic
 Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with
 Non-Small Cell Lung Cancer. Cancers. 2019;11(1):50.
- Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, et al. Dynamic Risk Profiling
 Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell. 2019;178(3):699713.e19.

Prognostic test for Multiple Myeloma

Murie et al.

Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han K-H, et al. Feasibility of dynamic risk
assessment for patients with repeated trans-arterial chemoembolization for hepatocellular
carcinoma. BMC Cancer. 2019;19:363.

Pitoia F, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid
cancer. Endocrine-Related Cancer. 2019;26(10):R553-R66.

Wall MA, Turkarslan S, Wu W-J, Danziger SA, Reiss DJ, Mason MJ, et al. Genetic
program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma. npj
Precision Oncology. 2021;5(1):1-15.

716 26. US National Institutes of Health. Relating clinical outcomes in multiple myeloma to
717 personal assessment of genetic profile (CoMMpass). Clinical Trials website.
718 https://clinicaltrials.gov/ct2/show/NCT01454297.

719 27. Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple
720 myeloma: prognostic implications and current clinical strategies. Blood Cancer Journal.
721 2012;2(9):e89-e.

Ashby C, Boyle EM, Bauer MA, Mikulasova A, Wardell CP, Williams L, et al. Structural
variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer
J. 2022;12(5):85.

Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, et al. The MicroArray
Quality Control (MAQC)-II study of common practices for the development and validation of
microarray-based predictive models. Nature Biotechnology. 2010;28(8):827-38.

30. Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, et al. Bone
marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple
myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med.
2020;17(11):e1003323.

31. Coffey DG, Cowan AJ, DeGraaff B, Martins TJ, Curley N, Green DJ, et al. HighThroughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for
Multiple Myeloma. JCO precision oncology. 2021;5:PO.20.00442.

Huang Z, Zhang H, Boss J, Goutman SA, Mukherjee B, Dinov ID, et al. Complete hazard
ranking to analyze right-censored data: An ALS survival study. PLOS Computational Biology.
2017;13(12):e1005887.

738 33. Zou H, Hastie T. Regularization and Variable Selection via the Elastic Net. Journal of the
739 Royal Statistical Society Series B (Statistical Methodology). 2005;67(2):301-20.

740 34. bswhite. bswhite/Celgene-Multiple-Myeloma-Challenge-Baseline-Models. 2019.

Prognostic test for Multiple Myeloma

Murie et al.

35. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. IMWG
consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-77.

743 36. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for
744 clinical practice. Blood Cancer J. 2015;5(10):e365.

745 37. Rajkumar SV. Multiple myeloma: Every year a new standard? Hematol Oncol. 2019;37
746 Suppl 1(Suppl 1):62-5.

Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, et al. Gene
expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper
cells and vascular endothelial growth factor deregulation. Cancer Research. 2007;67(22):1070310.

39. Dürig J, Bug S, Klein-Hitpass L, Boes T, Jöns T, Martin-Subero JI, et al. Combined single
nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies
novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis
of T-cell prolymphocytic leukemia with inv(14)(q11q32). Leukemia. 2007;21(10):2153-63.

40. Concannon CG, Koehler BF, Reimertz C, Murphy BM, Bonner C, Thurow N, et al.
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA
pathway. Oncogene. 2007;26(12):1681-92.

41. Osman I, Bajorin DF, Sun T-T, Zhong H, Douglas D, Scattergood J, et al. Novel blood
biomarkers of human urinary bladder cancer. Clinical Cancer Research: An Official Journal of the
American Association for Cancer Research. 2006;12(11 Pt 1):3374-80.

42. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment
of multiple myeloma. Blood. 1992;80(4):887-90.

43. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral SelinexorDexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019;381(8):72738.

766 44. Neumeister P, Schulz E, Pansy K, Szmyra M, Deutsch AJ. Targeting the
767 Microenvironment for Treating Multiple Myeloma. Int J Mol Sci. 2022;23(14).

45. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis.Nat Med. 2013;19(11):1423-37.

46. van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V. From MGUS to Multiple
Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. Cancer Res. 2018;78(10):244956.

47. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev774 Cancer. 2017;17(9):543-56.

Prognostic test for Multiple Myeloma

Murie et al.

48. Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS
and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018;15(4):219-33.

Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et al. Gaps and
opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus
recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J.
2022;12(6):98.

50. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy
for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and RiskAdapted Therapy. Mayo Clin Proc. 2017;92(4):578-98.

51. Hernandez-Rivas JA, Rios-Tamayo R, Encinas C, Alonso R, Lahuerta JJ. The changing
landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
Biomark Res. 2022;10(1):1.

52. Delgado-Calle J, Kurihara N, Atkinson EG, Nelson J, Miyagawa K, Galmarini CM, et al.

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by
direct effects on osteoclasts. Oncotarget. 2019;10(28):2709-21.

Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, et al. Aplidin, a
marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer
Research. 2008;68(13):5216-25.

54. Shah V, Sherborne AL, Johnson DC, Ellis S, Price A, Chowdhury F, et al. Predicting
ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant
eligible myeloma XI trial patients. Leukemia. 2020:1-6.